English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Thursday, January 7, 2021
APOLLOMICS(冠科美博)UPROLESELAN(APL-106)注射液獲得國家CDE突破性療法認定
APOLLOMICS(冠科美博)UPROLESELAN(APL-106)注射液获得国家CDE突破性疗法认定
APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia
Thursday, November 12, 2020
APOLLOMICS(冠科美博)APL-102 I期临床研究获得中国新药临床试验批件
APOLLOMICS(冠科美博)APL-102 I期臨床研究獲得中國新藥臨床試驗批件
Friday, November 6, 2020
APOLLOMICS(冠科美博)完成1.24億美元C輪融資
APOLLOMICS(冠科美博)完成1.24亿美元C轮融资
Monday, September 28, 2020
APOLLOMICS(冠科美博)APL-106治療急性髓系白血病的III期臨床橋接研究獲得中國新藥臨床試驗批件
APOLLOMICS(冠科美博)APL-106治疗急性髓系白血病的III期临床桥接研究获得中国新药临床试验批件

Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575